论文部分内容阅读
目的 比较不同抗精神病药物对女性首发精神分裂症患者糖、脂代谢和体质量的影响.方法 选取女性首发精神分裂症患者120例,采用随机数字表法分为三组,第1组(奥氮平组)患者给予奥氮平治疗,第2组(齐拉西酮组)予齐拉西酮治疗,第3组(利培酮组)予利培酮治疗,统计分析三组患者空腹血糖、总胆固醇(TC)、甘油三酯(TG)、体质量指数(BMI)变化情况.结果 三组患者治疗8周末与治疗前比较,奥氮平组、利培酮组空腹血糖升高明显,差异有统计学意义(t=-2.81,P＜0.01;t=-1.76,P＜0.05),齐拉西酮组血糖变化差异无统计学意义(t=-0.56,P＞0.05);治疗8周末与治疗前BMI比较,奥氮平组、利培酮组差异有统计学意义(t=-3.62,P＜0.01;t=-2.95,P＜0.01),齐拉西酮组患者BMI差异无统计学意义(t=-1.26,P＞0.05);三组患者治疗8周末TG、TC与治疗前比较,奥氮平组差异有统计学意义(t=-3.89,P＜0.01;t=-3.89,P＜0.01),利培酮组、齐拉西酮组差异无统计学意义(t=-1.64,P＞0.05;t=-1.06,P＞0.05;t=-0.55,P＞0.05;t=-0.62,P＞0.05).结论 齐拉西酮治疗女性首发精神分裂症,对糖、脂代谢及体质量影响小,患者依从性高,较其他非典型抗精神病药更有优势.“,”Objective To study the effects of atypical antipsychotic drugs on glucose and lipid metabolism and body weight in female patients with schizophrenia.Methods 120 patients with schizophrenia were randomly divided into three groups according to the number randomized method.Group 1 (olanzapine group) was treated with olanzapine,group 2(ziprasidone group) was treated with ziprasidone,group 3 (risperidone group) was treated with risperidone.The total cholesterol (TC),triglyceride (TG) and body mass index (BMI) in the three groups were analyzed retrospectively.Results After treatment for 8 weeks,the fasting blood glucose of the olanzapine group and risperidone group increased significantly compared with before treatment,the differences were statistically significant(t =-2.81,P ＜ 0.01;t =-1.76,P ＜ 0.05),the blood glucose of the ziprasidone group had no significant change (t =-0.56,P ＞ 0.05).After treatment for 8 weeks,the BMI of the olanzapine group and risperidone group had statistically significant difference compared with before treatment (t =-3.62,P ＜ 0.01;t =-2.95,P ＜ 0.01),the difference of the ziprasidone group was not significant in BMI (t =-1.26,P ＞ 0.05).After treatment for 8 weeks,the TG,TC levels of the olanzapine group had statistically significant differences compared with before treatment (t =-3.89,P ＜ 0.01;t =-3.89,P ＜ 0.01),which of the risperidone group and ziprasidone group had no statistically significant differences (t =-1.64,P ＞ 0.05;t =-1.06,P ＞ 0.05;t =-0.55,P ＞ 0.05;t =-0.62,P ＞ 0.05).Conclusion Ziprasidone in the treatment of female first episode schizophrenia,has less influence on sugar,lipid metabolism and weight,with high compliance and more advantages compared with other atypical antipsychotics.